US Drug Recall Register
Class III · Low risk Terminated Initiated Aug 4, 2016 (10 years ago)

buPROPion Hydrochloride Extended-Release Tablets

Class III — Low risk. Unlikely to cause harm, but violates FDA regulations.

Why it was recalled

Failed dissolution specifications - the out of specification result for dissolution was identified during 3 month stability testing.

What was recalled

buPROPion Hydrochloride Extended-Release Tablets, USP (XL), 300mg, 500-count bottle, Rx only, Manufactured by: Cadila Healthcare Ltd., Ahmedabad, India For BluePoint Laboratories, NDC 68001-264-03

Recalling firm
Amerisource Health Services
NDC code
68001-264-03
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1501-2016

What should you do? A recall doesn't always mean your specific bottle is affected - it often applies to certain lots only. Check the lot number on your package against the FDA notice, and talk to your pharmacist before stopping any medication.

Other Chloride recalls

See all
Class II · Moderate risk Ongoing

Clindamycin Palmitate Hydrochloride for Oral Solution

Reason Presence of Foreign Substance: presence of particles and white flakes in the reconstituted bottles.

Heritage Pharmaceuticals Inc NDC 23155-603-51 D-0768-2026
Class II · Moderate risk Ongoing

Dicyclomine Hydrochloride Capsules

Reason shortfill; reports of empty capsules.

Aurobindo Pharma USA Inc NDC 59651-719-99 D-0733-2026
Class II · Moderate risk Ongoing

Naropin

Reason Presence of Particulate Matter: Hair was found in products

Fresenius Kabi USA, LLC D-0727-2026
Class II · Moderate risk Ongoing

Rohto Cooling Eye Drops Cool Relief

Reason Lack of Assurance of Sterility

Rohto-Mentholatum (Vietnam) Co., Ltd. NDC 10742-8141-1 D-0722-2026
Class II · Moderate risk Ongoing

Rohto Cooling Eye Drops Optic Glow

Reason Lack of Assurance of Sterility

Rohto-Mentholatum (Vietnam) Co., Ltd. NDC 10742-8160-1 D-0718-2026